Fig. 3: EB-42168 inhibits LRRK2 pSer1292 in G2019S-LRRK2 overexpressing cells at concentrations that also inhibited pSer935.
From: G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
a Representative western blot of G2019S-LRRK2 cells treated with DMSO, 10 nM, 100 nM or 1 µM MLi-2 for 2 h and assessed for LRRK2 pSer1292 and full-length LRRK2. b Representative western blot of G2019S-LRRK2 cells treated with DMSO, 10 nM, 100 nM or 1 µM EB-42168 for 2 h and assessed for LRRK2 pSer1292 and full-length LRRK2. c Quantification of western blots demonstrate a 65%, 90% and 95% decrease in LRRK2 pSer1292 levels with increasing concentration of MLi-2 in G2019S-LRRK2 expressing cells. d Quantification of western blots demonstrate a 30%, 65% and 85% decrease in LRRK2 pSer1292 levels with 10 nM, 100 nM and 1 µM respectively of EB-42168 in G2019S-LRRK2 expressing cells. Data are presented as mean ± SEM. n = 3 replicates. (*p < 0.0001 determined by one-way ANOVA). GS-LRRK2 G2019S-LRRK2.
